<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091858</url>
  </required_header>
  <id_info>
    <org_study_id>20010103</org_study_id>
    <nct_id>NCT00091858</nct_id>
    <nct_alias>NCT00098696</nct_alias>
  </id_info>
  <brief_title>Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of darbepoetin alfa versus placebo in
      reducing the occurrences of red blood cell transfusions in subjects with anemia of cancer who
      are not receiving chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrences of red blood cell transfusion</measure>
    <time_frame>from study day 29 (week 5) to week 17</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of first red blood cell transfusion</measure>
    <time_frame>from week 5 (study day 29) to week 17 (study day 119)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin concentration measured</measure>
    <time_frame>from baseline (study day 1) to EOTP</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and serious adverse events</measure>
    <time_frame>throughout study for subjects who received at least 1 dose of investigational product</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>deaths on study and deaths in long-term follow-up period for subjects who received at least 1 dose of investigational product</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, if any, of neutralizing antibody formation to investigational product</measure>
    <time_frame>throughout study for subjects who received at least 1 dose of investigational product</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment>1000</enrollment>
  <condition>Anemia</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Darbepoetin alfa 6.75 mcg/kg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Q4W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin Alfa</intervention_name>
    <description>6.75 mcg/kg Q4W</description>
    <arm_group_label>Darbepoetin alfa 6.75 mcg/kg Q4W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Q4W</description>
    <arm_group_label>Placebo Q4W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects with non-myeloid malignancies

          -  anemia due to cancer

          -  ECOG status 0 to 2

          -  greater than or equal to 4-month expectancy

          -  greater than or equal to 18 years and of legal age for informed consent

          -  screening hemoglobin concentration less than or equal to 11.0g/dL

          -  adequate serum folate and vitamin B12

          -  adequate renal and liver function

          -  written informed consent

        Exclusion Criteria:

          -  subjects currently receiving or planned to receive cytotoxic chemotherapy or
             myelosuppressive radiotherapy during the study or within 4 weeks before randomization

          -  in complete remission, as determined by the investigator

          -  subjects who have other diagnoses not related to the cancer which cause anemia (eg.
             gastrointestinal bleeding, renal disease, etc)

          -  documented history of pure red cell aplasia

          -  Known history of seizure disorder

          -  cardiac condition: uncontrolled angina, congestive heart failure, known ejection
             fraction less than 40%, or uncontrolled cardiac arrhythmia

          -  uncontrolled hypertension

          -  clinically significant systemic infection or chronic inflammatory disease present at
             the time of randomization

          -  iron deficiency

          -  known positive test for HIV infection

          -  previously suspected of or confirmed to have neutralizing antibodies to rHuEPO or
             darbepoetin alfa

          -  received rHuEPO or darbepoetin alfa therapy within 4 weeks of randomization

          -  less than 30 days since receipt of any investigational drug or device that is not
             approved by the applicable regulatory authority

          -  pregnant or breast feeding

          -  subject of reproductive potential who is not using adequate contraceptive precautions

          -  known hypersensitivity to mammalian-derived product or any other ingredients in the
             investigational product

          -  previously randomized into this study

          -  concerns for subject's compliance with the protocol procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://www.aranesp.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <results_reference>
    <citation>Smith RE Jr, Aapro MS, Ludwig H, Pint√©r T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008 Mar 1;26(7):1040-50. doi: 10.1200/JCO.2007.14.2885. Epub 2008 Jan 28.</citation>
    <PMID>18227526</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2004</study_first_submitted>
  <study_first_submitted_qc>September 20, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2004</study_first_posted>
  <last_update_submitted>May 6, 2013</last_update_submitted>
  <last_update_submitted_qc>May 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer-related anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

